Added to YB: 2025-09-10
Pitch date: 2025-09-09
ATYR [neutral]
aTyr Pharma, Inc.
-85.41%
current return
Author Info
AnthonyStaj shares thoughts and musings on biotech, mostly. L/S, not afraid of indication, highly focused on clinical and commercial analysis. Sign up for the newsletter.
Company Info
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Market Cap
$73.8M
Pitch Price
$5.32
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.06
P/E
-0.89
EV/Sales
-22.27
Sector
Biotechnology
Category
special_situation
ATYR Follow-up
ATYR short (update): Predicts EFZO-FIT ph3 failure due to baseline imbalances in ph1/2, weak NRP2 binding (no KD reported, only 30nM EC50 on overexpressing cells), poor P.acnes preclinical efficacy, & potential CCR5-mediated lymphocyte recruitment worsening disease. Estimates placebo arm achieves ~75% steroid-free at wks45-48 vs similar drug performance.
Read full article (25 min)